There more than 7000 rare diseases that affect more than 350 million people around the world. For the longest time now, the biotechnology and pharmaceutical sectors had neglected these rare diseases as they deemed them not to be economically feasible to try and find a cure. Today, this is not the case thanks to the entrepreneur and biopharma industry expert Marc Beer. As an entrepreneur, he is the Founder of ViaCell, which he should to PerkinElmer, and Renovia, his current venture. He is also the CEO and Chairman of Renovia.

 

A New Dawn

 

This accomplished biopharma entrepreneur and industry expert have been committed to bringing a new dawn to the sector. From his first entrepreneurial venture, ViaCell, he has been keen on finding treatments for rare diseases that have been neglected by mainstream biopharma companies. He founded ViaCell in 2000 and led the company to become a biotechnology industry-leader in addressing rare disorders.

 

ViaCell focused on collecting umbilical cord blood stem cells and preserving them for the development of treatments for different diseases. By 2005, this company had grown to have more than 300 employees, and Marc Beer decided to take it public. In 2007, he sold the company to PerkinElmer for $300 million. This move ushered him to the next phase of his entrepreneurial endeavor.

 

Focusing on Women’s Health

 

In 2016, Marc Beer, together with his partners, Yolanda Lorie and Ray Iglesias, founded Renovia. This is a med-tech company that is based in Boston and focuses on women’s health. Renovia is committed to developing therapeutic and diagnostic solutions for women’s health complications.

 

The idea for Renovia came to Marc after he received a call from Dr. Ray Iglesias, a top-notch gynecologist with more than 35 years of experience performing pelvic floor surgeries. Ray wanted his helping in finding a solution that would help women with pelvic floor disorders avoid surgery. After founding Renovia, the first product that they released was a device that would be the first-line diagnosis and treatment for pelvic floor disorders. The FDA approved this device in April 2018, and the company is currently working on an upgraded version.

 

In the United States alone, pelvic disorders like urinary incontinence, pelvic organ prolapse, and fecal incontinence affect up to 25% of women. The numbers are much worse in developing countries where most women can’t access quality medical care. Marc Beer hopes that through Renovia, he can make a difference in the lives of women across the world.

 

About Marc

 

This entrepreneur has been in the biopharma sector for more than three decades, and most of this time, he spent as a business executive specializing in the development and commercialization of biotechnology. Marc Beer graduated from Miami University with a Bachelor of Science in Business degree in 1987. After his graduation, he went on to work for various companies before becoming an entrepreneur. Learn more: https://www.thepharmaletter.com/profile/marc-beer

 

Besides entrepreneurship, Marc is also a member of the Miami University Business Advisory Council. In addition to this, he has previously served as a Notre Dame Graduate Studies Research Advisory Council and Notre Dame Research and Commercialization Advisory Committee board member.

Follow Marc Beer on Facebook